Triazolotriazines as kinase inhibitors

1. A compound of Formula I:

or pharmaceutically acceptable salt thereof, wherein:

Cy 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 —W—X—Y-Z;

Cy 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 —W′—X′—Y′-Z′;

A is H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR A , SR A , C(O)R B , C(O)NR C R D , C(O)OR A , OC(O)R B , OC(O)NR C R D , NR C R D , NR C C(O)R B , NR C C(O)NR C R D , NR C C(O)OR A , S(O)R B , S(O)NR C R D , S(O) 2 R B , NR C S(O) 2 R B , or S(O) 2 NR C R D ;

R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 7-membered cycloalkyl group or 3- to 7-membered heterocycloalkyl group, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from Q, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(OR e ) 2 , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents selected from Q, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(O)R e R f , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d ;

Q is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, halosulfanyl, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)NR c1 R d1 , NR c1 C(O)OR a1 , C(═NR g1 )NR c1 R d1 , NR c1 C(═NR g1 )NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , NR c1 S(O) 2 R b1 , and S(O) 2 NR c1 R d1 ;

W and W′ are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, O, S, NR h , CO, COO, CONR h , SO, SO 2 , SONR h and NR h CONR i , wherein each of the C 1-6 alkylene, C 2-6 alkenylene, and C 2-6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;

X and X′ are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO 2 , OH, C 1-6 alkyl, C 1-6 haloalkyl, C 2-8 alkoxyalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 2-8 alkoxyalkoxy, cycloalkyl, heterocycloalkyl, C(O)OR j , C(O)NR h R i , amino, C 1-6 alkylamino, and C 2-8 dialkylamino;

Y and Y′ are independently absent or independently selected from C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, O, S, NR h , CO, COO, CONR h , SO, SO 2 , SONR h , and NR h CONR i , wherein each of the C 1-6 alkylene, C 2-6 alkenylene, and C 2-6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, and C 2-8 dialkylamino;

Z and Z′ are independently selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O) b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , C(═NR g2 )NR c2 R d2 , NR c2 C(═NR g2 )NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , NR c2 S(O) 2 R b2 , S(O) 2 NR c2 R d2 , aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, halosulfanyl, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , C(═NR g2 )NR c2 R d2 , NR c2 C(═NR g2 )NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , NR c2 S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

wherein two adjacent —W—X—Y-Z, together with the atoms to which they are attached, optionally form a fused 4-, 5-, 6-, or 7-membered cycloalkyl ring or a fused 4-, 5-, 6-, or 7-membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , C(═NR g2 )NR c2 R d2 , NR c2 C(═NR g2 )NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , NR c2 , S(O) 2 R b2 , S(O) 2 NR c2 R d2 , aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;

wherein two adjacent —W′—X′—Y′-Z′, together with the atoms to which they are attached, optionally form a fused 4-, 5-, 6-, or 7-membered cycloalkyl ring or a fused 4-, 5-, 6-, or 7-membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , C(═NR g2 )NR c2 R d2 , NR c2 C(═NR g2 )NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , NR c2 S(O) 2 R b2 , S(O) 2 NR c2 R d2 , aryl, cycloalkyl, heteroaryl, and heterocycloalkyl;

R A is H, C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;

R B is H, C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;

R C and R D are independently selected from H, C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;

or R C and R D together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, and C 1-4 alkyl;

R a , R a1 , R a2 , are R a3 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

R b , R b1 , R b2 , are R b3 are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

R c and R d are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

or R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

R c1 and R d1 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

or R c1 and R d1 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;

R c2 and R d2 are independently selected from H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl, wherein said C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a3 , C(O)R b3 , S(O) 2 R b3 , alkoxyalkyl, and alkoxyalkoxy;

or R c2 and R d2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a3 , C(O)R b3 , S(O) 2 R b3 , alkoxyalkyl, and alkoxyalkoxy;

R e is H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, (C 1-6 alkoxy)-C 1-6 alkyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl;

R f is H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl;

R g , R g1 , and R g2 are independently selected from H, CN, and NO 2 ;

R h and R i are independently selected from H and C 1-6 alkyl; and

R j is H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.

2. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 1 is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 —W—X—Y-Z.

3. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 1 is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 -Z.

4. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 1 is aryl or heteroaryl, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, OH, and C 1-4 alkoxy.

5. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 1 is phenyl or quinolinyl, each optionally substituted by 1, 2, 3, 4, or 5 —W—X—Y-Z.

6. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 2 is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4, or 5 —W′—X′—Y′-Z′.

7. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 2 is phenyl optionally substituted by 1, 2, 3, 4, or 5 —W′—X′—Y′-Z′.

8. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Cy 2 is phenyl optionally substituted by 1, 2, 3, 4, or 5 -Z′.

9. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein A Is H, halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, NO 2 , OR A , or NR C R D .

10. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein A Is H or NR C R D .

11. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 7-membered cycloalkyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from Q, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(OR e ) 2 , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents selected from Q, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(OR e ) 2 , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d .

12. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 and R 2 together with the carbon atom to which they are attached form a cyclopropyl group optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from Q, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(OR e ) 2 , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents selected from Q, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , C(═NR g )NR c R d , NR c C(═NR g )NR c R d , P(R f ) 2 , P(OR e ) 2 , P(O)R e R f , P(O)OR e OR f , S(O)R b , S(O)NR c R d , S(O) 2 R b , NR c S(O) 2 R b , and S(O) 2 NR c R d .

13. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 and R 2 together with the carbon atom to which they are attached form a 3- to 7-membered cycloalkyl group.

14. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 and R 2 together with the carbon atom to which they are attached form a cyclopropyl group.

15. The compound of claim 1 , or pharmaceutically acceptable salt thereof, having Formula II:

16. The compound of claim 1 , or pharmaceutically acceptable salt thereof, having Formula IIIa or IIIb:

17. A composition comprising a compound of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A method of treating a breast cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-7-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 which is 4-[1-(6-Phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl)cyclopropyl]phenol, or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 which is 4-[1-(7-Phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)cyclopropyl]phenol, or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 which is 6-(4-Fluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 which is 7-(4-Fluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-(4-morpholin-4-ylphenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

26. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-7-(4-morpholin-4-ylphenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

27. The compound of claim 1 which is 6-(4-Chlorophenyl)-3-[1 -(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 which is 7-(4-Chlorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

29. The compound of claim 1 which is 4-3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylphenol, or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-yl}phenol, or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1 which is 4-3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylbenzonitrile, or a pharmaceutically acceptable salt thereof.

32. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-yl}benzonitrile, or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1 which is N-(4-3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylphenyl)acetamide (8), or a pharmaceutically acceptable salt thereof.

34. The compound of claim 1 which is N-(4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-yl}phenyl)acetamide, or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1 which is 6-(4-Methoxyphenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1 which is 7-(4-Methoxyphenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1 which is 6-(2,4-Difluorophenyl)-3-[1 -(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1 which is 7-(2,4-Difluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1 which is 6-(3,4-Dichlorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1 which is 7-(3,4-Dichlorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1 which is 6-(3,4-Difluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1 which is 7-(3,4-Difluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

43. The compound of claim 1 which is 6-(3-Methoxyphenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

44. The compound of claim 1 which is 7-(3-Methoxyphenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

45. The compound of claim 1 which is 6-(3-Bromophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

46. The compound of claim 1 which is 7-(3-Bromophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

47. The compound of claim 1 which is 6-(5 -Bromo-2-thienyl)-3 -[1 -(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

48. The compound of claim 1 which is 7-(5-Bromo-2-thienyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

49. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-(4-nitrophenyl) [1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

50. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-7-(4-nitrophenyl) [1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

51. The compound of claim 1 which is 6-(4-Bromophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1 which is 7-(4-Bromophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

53. The compound of claim 1 which is 4-3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylaniline, or a pharmaceutically acceptable salt thereof.

54. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-yl}aniline, or a pharmaceutically acceptable salt thereof.

55. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-[3-(1-methyl-1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

56. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-7-[3-(1-methyl-1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

57. The compound of claim 1 which is 3-[1 -(4-Methoxyphenyl)cyclopropyl]-6-[3-(1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

58. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-7-[3-(1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

59. The compound of claim 1 which is tert-Butyl (3′-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylbiphenyl-4-yl)carbamate, or a pharmaceutically acceptable salt thereof.

60. The compound of claim 1 which is tert-Butyl (3′- {3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-yl}biphenyl-4-yl)carbamate, or a pharmaceutically acceptable salt thereof.

61. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-[4-(1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

62. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-[4-(1-methyl-1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

63. The compound of claim 1 which is 3-[1-(4-Bromophenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

64. The compound of claim 1 which is 3-[1-(3-Bromophenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

65. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

66. The compound of claim 1 which is 6-[1-(6-Phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl)cyclopropyl]quinoline, or a pharmaceutically acceptable salt thereof.

67. The compound of claim 1 which is 3-[1 -(4-Chlorophenyl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

68. The compound of claim 1 which is 3-[1-(2,4-Dichlorophenyl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

69. The compound of claim 1 which is 3-[1-(3-Bromophenyl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

70. The compound of claim 1 which is 3-[1-(4-Bromophenyl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

71. The compound of claim 1 which is 3-[1-(2-Chlorophenyl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

72. The compound of claim 1 which is 6-(4-Fluorophenyl)-3-[1-(2-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

73. The compound of claim 1 which is 6-(4-Fluorophenyl)-3-[1-(3-fluorophenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

74. The compound of claim 1 which is 6-(4-Fluorophenyl)-3-{1-[3-(trifluoromethyl)phenyl]cyclopropyl}[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

75. The compound of claim 1 which is 3-[1-(2-Chloro-6-fluorophenyl)cyclopropyl]- 6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

76. The compound of claim 1 which is 3-[l -(1,3-Benzodioxol-5 -yl)cyclopropyl]-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

77. The compound of claim 1 which is 4-{1 -[6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

78. The compound of claim 1 which is 6-{1-[6-(4-Fluorophenyl)[1,2,4]triazolo[4,3 -b][1,2,4]triazin-3-yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

79. The compound of claim 1 which is 6-{1-[6-(3 -Bromophenyl) [1,2,4]triazolo[4,3 -b][1,2,4]triazin-3 -yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

80. The compound of claim 1 which is 6- {1- [6-(4-Bromophenyl) [1,2,4]triazolo[4,3 -b][1,2,4]triazin-3 -yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

81. The compound of claim 1 which is 3-[3-(1-Quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzonitrile, or a pharmaceutically acceptable salt thereof.

82. The compound of claim 1 which is 4-[3-(1-Quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzonitrile, or a pharmaceutically acceptable salt thereof.

83. The compound of claim 1 which is 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazin-7-amine, or a pharmaceutically acceptable salt thereof.

84. The compound of claim 1 which is 6-(4-Fluorophenyl)-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-7-amine, or a pharmaceutically acceptable salt thereof.

85. The compound of claim 1 which is 6-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}-1,3-benzothiazol-2-amine, or a pharmaceutically acceptable salt thereof.

86. The compound of claim 1 which is 1-(4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.

87. The compound of claim 1 which is N-Cyclopropyl-4- {3-[1 -(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}benzamide, or a pharmaceutically acceptable salt thereof.

88. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide, or a pharmaceutically acceptable salt thereof.

89. The compound of claim 1 which is N-(trans-4-Hydroxycyclohexyl)-4-3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-ylbenzamide, or a pharmaceutically acceptable salt thereof.

90. The compound of claim 1 which is Ethyl 4-[(4-{3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}benzoyl)amino]piperidine- 1-carboxylate, or a pharmaceutically acceptable salt thereof.

91. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}-N-(pyridin-2-ylmethyl)benzamide, or a pharmaceutically acceptable salt thereof.

92. The compound of claim 1 which is Ethyl 1-[(4-{3-[1-(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}benzoyl)amino]cyclopropanecarboxylate, or a pharmaceutically acceptable salt thereof.

93. The compound of claim 1 which is N-[1-(6-Fluoropyridin-2-yl)pyrrolidin-3-yl]-4-{3-[1 -(4-methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}benzamide, or a pharmaceutically acceptable salt thereof.

94. The compound of claim 1 which is 4-{3-[1-(4-Methoxyphenyl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl-N′-pyridin-2-yl}benzohydrazide, or a pharmaceutically acceptable salt thereof.

95. The compound of claim 1 which is 6-(1-{6-[3-(1H-imidazol-1-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

96. The compound of claim 1 which is 6-(1-{6-[4-(1H-imidazol-1-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

97. The compound of claim 1 which is 3-{4-[3-(1-Quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1,3-oxazolidin-2-one, or a pharmaceutically acceptable salt thereof.

98. The compound of claim 1 which is 6-(1-{6-[3-(6-Methoxypyridin-3-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

99. The compound of claim 1 which is N,N-Dimethyl-5-{3-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

100. The compound of claim 1 which is N-Ethyl-5-{3-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

101. The compound of claim 1 which is N-Methyl-2-(4-{3-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol- 1-yl)acetamide, or a pharmaceutically acceptable salt thereof.

102. The compound of claim 1 which is 2-(4-{3-[3-(1-Quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol- 1 -yl)-N-(tetrahydrofuran-3 -yl)acetamide, or a pharmaceutically acceptable salt thereof.

103. The compound of claim 1 which is N-(1-Pyridin-2-ylethyl)-2-(4-{3-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1-yl)acetamide, or a pharmaceutically acceptable salt thereof.

104. The compound of claim 1 which is N,N-Dimethyl-2-(4-{3-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol- 1-yl)acetamide, or a pharmaceutically acceptable salt thereof.

105. The compound of claim 1 which is N-Methyl-2-(4-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1 -yl)acetamide, or a pharmaceutically acceptable salt thereof.

106. The compound of claim 1 which is N-Isopropyl-2-(4-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1-yl)acetamide, or a pharmaceutically acceptable salt thereof.

107. The compound of claim 1 which is N-(Cyclopropylmethyl)-2-(4-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol- 1-yl)acetamide, or a pharmaceutically acceptable salt thereof.

108. The compound of claim 1 which is N-Isopropyl-2-methyl-2-(4-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1-yl)propanamide, or a pharmaceutically acceptable salt thereof.

109. The compound of claim 1 which is 6-[1-(6-{4-[1-(1,1-Dimethyl-2-oxo-2-pyrrolidin-1 -ylethyl)-1H-pyrazol-4-yl]phenyl}[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)cyclopropyl]quinoline, or a pharmaceutically acceptable salt thereof.

110. The compound of claim 1 which is (2R)-N,N-Dimethyl-2-(4-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1-yl)propanamide, or a pharmaceutically acceptable salt thereof.

111. The compound of claim 1 which is (2S)-N,N-Dimethyl-2-(4-{4-[3-(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-1H-pyrazol-1-yl)propanamide, or a pharmaceutically acceptable salt thereof.

112. The compound of claim 1 which is 6-(3-Bromophenyl)-3-[1-(3-methyl[1,2,4]triazolo[4,3 -a]pyridin-6-yl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

113. The compound of claim 1 which is 6-1-[6-(4-Bromo-3-fluorophenyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl]cyclopropylquinoline, or a pharmaceutically acceptable salt thereof.

114. The compound of claim 1 which is 6-(1-{6-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl][1,2,4]triazolo[4,3 -b][1,2,4]triazin-3 -yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

115. The compound of claim 1 which is 5-{2-Fluoro-4-[3-(1-quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}-N,N-dimethylpyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

116. The compound of claim 1 which is 5-{2-Fluoro-4-[3-(1-quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridin-2-amine, or a pharmaceutically acceptable salt thereof.

117. The compound of claim 1 which is Methyl (5- {2-fluoro-4-[3-(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridin-2-yl)carbamate, or a pharmaceutically acceptable salt thereof.

118. The compound of claim 1 which is 3-[l -(1,3 -Benzothiazol-6-yl)cyclopropyl]-6-(4-bromophenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.

119. The compound of claim 1 which is 4-{3-[1-(1,3-Benzothiazol-6-yl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}-N-{(1 S)-1-[(dimethylamino)carbonyl]propyl}benzamide, or a pharmaceutically acceptable salt thereof.

120. The compound of claim 1 which is 4-{3-[1-(1,3-Benzothiazol-6-yl)cyclopropyl][1,2,4 ]triazolo[4,3-b][1,2,4]triazin-6-yl}-N-{(1 S)-1- [(dimethylamino)carbonyl]-2-methylpropyl}benzamide, or a pharmaceutically acceptable salt thereof.

121. The compound of claim 1 which is 4-{3-[1-(1,3-Benzothiazol-6-yl)cyclopropyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}-N-{(1 S)- 1- [(dimethylamino)carbonyl]-2,2-dimethylpropyl}benzamide, or a pharmaceutically acceptable salt thereof.

122. The compound of claim 1 which is 6-(1-{6-[4-(1-Methyl-1H-pyrazol-4-yl)phenyl][1,2,4]triazolo[4,3 -b][1,2,4]triazin-3-yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

123. The compound of claim 1 which is N-Methyl-5-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

124. The compound of claim 1 which is N,N-Dimethyl-5-{4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]phenyl}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

125. The compound of claim 1 which is 6-(1-{6-[4-(1H-pyrazol-1-yl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

126. The compound of claim 1 which is N-(Cyclopropylmethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

127. The compound of claim 1 which is N-Lthyl-4- [3 -(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

128. The compound of claim 1 which is N,N-Dimethyl-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

129. The compound of claim 1 which is N-Cyclopropyl-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

130. The compound of claim 1 which is N-(Pyridin-2-ylmethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

131. The compound of claim 1 which is Ethyl 4-{4-[3-(1-Quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzoyl}piperazine- 1-carboxylate, or a pharmaceutically acceptable salt thereof.

132. The compound of claim 1 which is 6-(1-{6-[4-(Pyrrolidin-1-ylcarbonyl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

133. The compound of claim 1 which is 6-[1-(6-{4-[(3,3-Difluoropyrrolidin-1-yl)carbonyl]phenyl}[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)cyclopropyl]quinoline, or a pharmaceutically acceptable salt thereof.

134. The compound of claim 1 which is 6-{1-[6-(4-{[3-(3-Fluorophenyl)pyrrolidin-1-yl]carbonyl}phenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

135. The compound of claim 1 which is 6-{1-[6-(4-{[(3S)-3-Fluoropyrrolidin-1-yl]carbonyl}phenyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]cyclopropyl}quinoline, or a pharmaceutically acceptable salt thereof.

136. The compound of claim 1 which is 4-[3-(1-Quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]-N-[(2S)-tetrahydrofuran-2-ylmethyl]benzamide, or a pharmaceutically acceptable salt thereof.

137. The compound of claim 1 which is N-(1 -Pyridin-2-ylcyclopropyl)-4-[3 -(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

138. The compound of claim 1 which is N-(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl]propyl-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

139. The compound of claim 1 which is N-{(1S)-1-[(Dimethylamino)carbonyl]-2,2-dimethylpropyl}-4-[3-(1 -quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

140. The compound of claim 1 which is N-[(1S)-1-(Azetidin-1-ylcarbonyl)-2,2-dimethylpropyl]-4-[3-(1 -quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

141. The compound of claim 1 which is N-[(1S)-2-Amino-1-methyl-2-oxoethyl]-4-[3-(1 -quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

142. The compound of claim 1 which is N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]- 4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

143. The compound of claim 1 which is N-Lthyl-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

144. The compound of claim 1 which is 2-Fluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof

145. The compound of claim 1 which is 2-Fluoro-N-(trans-4-hydroxycyclohexyl)-4-[3-(1 -quinolin-6-ylcyclopropyl) [1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

146. The compound of claim 1 which is 2-Fluoro-N-(2-methoxy-1,1-dimethylethyl)-4-[3 -(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

147. The compound of claim 1 which is N-Cyclopropyl-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

148. The compound of claim 1 which is 2-Fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

149. The compound of claim 1 which is 2-Fluoro-N,N-dimethyl-4-[3-(1-quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

150. The compound of claim 1 which is 6-(1-{6-[3-Fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl][1,2,4]triazolo[4,3-b][1,2,4]triazin-3 -yl}cyclopropyl)quinoline, or a pharmaceutically acceptable salt thereof.

151. The compound of claim 1 which is N-Methyl-N-2-[methyl(pyridin-2-yl)amino]ethyl-4- [3-(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.

152. The compound of claim 1 which is N-[(1R)-1-(4-Methyl-1,3-thiazol-2-yl)ethyl]- 4-[3 -(1 -quinolin-6-ylcyclopropyl)[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzamide, or a pharmaceutically acceptable salt thereof.